Tecan Group - Aktsia

Tecan Group AAQS 2024

Tecan Group AAQS

6

Tecan Group Dividenditootlus

0,46 %

Ticker

TECN.SW

ISIN

CH0012100191

WKN

922557

Tecan Group omab hetkel AAQS väärtuseks 6. Kõrget AAQS-i võib pidada positiivseks märgiks, et ettevõte areneb edukalt. Investorid võivad eeldada, et ettevõte on heas seisus kasumi teenimiseks. Teisest küljest on oluline vaadelda Tecan Group aktsia AAQS-i võrdluses saadud kasumite ja sama sektori teiste ettevõtetega. Kõrge AAQS ei ole absoluutne garantii positiivseks tulevikuks. Ainult nii on võimalik saada täielik ülevaade ettevõtte sooritusest. Ettevõtte arengu paremaks hindamiseks on oluline võrrelda AAQS-i sama sektori teiste ettevõtetega. Üldiselt peaksid investorid alati vaatlema ettevõtte AAQS-i seoses teiste näitajatega nagu kasum, EBIT, rahavoog ja muud, et teha põhjendatud investeerimisotsus.

Tecan Group Aktienanalyse

Mis teeb Tecan Group?

Tecan Group AG is a Swiss company specializing in the development and manufacture of laboratory automation systems. It was founded in 1980 in Männedorf, a suburb of Zurich, by engineer Heinz Abplanalp and currently employs approximately 1,400 people worldwide. Tecan's business model focuses on supporting customers in the medical and pharmaceutical research and development fields with laboratory process automation. The goal is to save time and costs while improving the quality of results. Tecan offers a wide range of products and services for this purpose. One of Tecan's key areas is the production of robotic systems for sample processing in clinical diagnostics and drug research. These systems can automatically fill, mix, separate, and analyze samples in tubes or microplates. Automating these processes minimizes errors and achieves significant time savings. Another area is the manufacturing of laboratory equipment and instruments, such as pipettes, microplate readers, or washing stations. These products enable laboratories to process a variety of samples quickly and accurately capture data. The products are sold under various brand names, including Tecan, Cavro, and Debiotech. A significant milestone in Tecan's history was the introduction of the first microplate reader in 1988. Since then, the company has continuously improved the technology and now offers a wide range of microplate readers for various applications. Another important development was the introduction of the Freedom EVO® robotics system in 2000, which has become a key tool in clinical diagnostics and drug research. Tecan also provides a range of service offerings, including installation, training, and maintenance of automated laboratory equipment. Additionally, the company offers customized automation solutions tailored to its customers' specific requirements. In recent years, Tecan has expanded into the field of liquid handling robotics to offer customers new opportunities to automate their workflows. This includes automatic pipetting systems that offer high precision and reproducibility, increasing productivity in research and development. Despite its long history, Tecan has faced some challenges in recent years. In 2021, the company acquired IDS Imaging Development Systems to expand its robotics systems in laboratory diagnostics and life sciences. Tecan also sees itself increasingly as part of the industry's digital transformation, relying on artificial intelligence, machine learning, robotics, and automation to support its customers in addressing the changing laboratory requirements. Overall, Tecan is an important player in the laboratory technology industry, earning a reputation with its robotic systems and automation solutions. The company has continuously evolved over the past decades and now offers its customers a wide range of products and services to optimize and accelerate their research and development processes. Tecan Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Sagedased küsimused Tecan Group aktsia kohta

Aktsiasäästuplaanid pakuvad investoritele atraktiivset võimalust pikema aja jooksul vara koguda. Üheks peamiseks eeliseks on nn keskmise maksumuse efekt: investeerides regulaarselt kindla summa aktsiatesse või aktsiafondidesse, ostetakse automaatselt rohkem osakuid siis, kui hinnad on madalad, ja vähem, kui need on kõrged. See võib aja jooksul viia soodsama keskmise hinna per osakuni. Lisaks võimaldavad aktsiasäästuplaanid ka väikeinvestoritel pääseda ligi kallimatele aktsiatele, kuna nendega saab liituda juba väikeste summadega. Regulaarne investeerimine soodustab ka distsiplineeritud investeerimisstrateegiat ja aitab vältida emotsionaalsete otsuste, nagu impulsiivne ostmine või müümine. Peale selle saavad investorid osa aktsiate võimalikust väärtuse kasvust ning dividendide väljamaksetest, mida saab reinvesteerida, mis tugevdab intressiintressi efekti ning seeläbi investeeritud kapitali kasvu.

Andere Kennzahlen von Tecan Group

Meie Tecan Group Käive-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Tecan Group Käive. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: